Results 121 to 130 of about 15,165 (218)

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7073-7082, August 2026.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

, 2005
Exploitation of glucose-dependent insulinotropic polypeptide (GIP) is hindered by its short biological half-life and rapid renal clearance. To circumvent these problems, two novel acylated N-terminally modified GIP analogues, N-pGluGIP(LysPAL16) and N ...
Flatt, P.R., Gault, V.A., Harriott, Patrick, Bailey, C.J., O'Harte, F.P.M., Irwin, Nigel, Green, Brian, Gault, Victor A., Flatt, Peter R., Irwin, N., Green, Brian D., Greer, Brett, Bailey, Clifford J., O'Harte, Finbarr P.M.   +13 more
core   +1 more source

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT‐J Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6639-6648, August 2026.
ABSTRACT Aims We evaluated the impact of tirzepatide on health‐related quality of life (HR‐QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT‐J trial. Materials and Methods Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle ...
Hiroaki Masuzaki, Hirotaka Nagashima, Tomotaka Shingaki, Tomonori Oura, Ichiro Tatsuno   +4 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

, 2006
Glucose-dependent insulinotropic polypeptide (GIP) is a physiological insulin releasing peptide. We have developed two novel fatty acid derivatized GIP analogues, which bind to serum albumin and demonstrate enhanced duration of action in vivo. GIP(Lys(16)
Flatt, P.R., Green, Brian, Gault, V.A., Harriott, Patrick, O'Hartet, F.P.M., Irwin, N., Greer, Brett, Bailey, C.J.   +7 more
core   +1 more source

Gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide signaling in adipose tissue

Journal of Diabetes Investigation, 2019
Shunsuke Yamane, Norio Harada
doaj   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7196-7206, August 2026.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source

Tirzepatide and Obesity: A Narrative Review

Advances in Human Biology
This research systematically evaluates the efficacy and safety of Tirzepatide (TZP), a novel dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptors, in treating obesity and diabetes with ...
Arya Singh, Rahnuma Ahmad, Kona Chowdhury, Mahendra Narwaria, Mainul Haque   +4 more
doaj   +1 more source

Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat‐Free and Skeletal Muscle Mass in Overweight or Obese Individuals—A Systematic Review With Pairwise Meta‐Analysis and Network Meta‐Analysis of Randomized Controlled Studies

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6810-6823, August 2026.
ABSTRACT Aims Calorie restriction (CR) reduces both fat mass and fat‐free mass (FFM), particularly skeletal muscle mass (SMM), which is essential for cardiometabolic health and preventing frailty. This study compares CR alone versus CR plus exercise (EX) on FFM and SMM in overweight/obese patients and examines the effects of different training modes ...
Magdalena Deller, Jan Weiershaus, Steffen Held, Christian Brinkmann   +3 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source